We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Provexis Plc | LSE:PXS | London | Ordinary Share | GB00B0923P27 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.075 | -11.54% | 0.575 | 0.55 | 0.60 | 0.60 | 0.60 | 0.60 | 2,870,364 | 16:35:20 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Food Preparations, Nec | 390k | -385k | -0.0002 | -30.00 | 13.31M |
Date | Subject | Author | Discuss |
---|---|---|---|
09/5/2018 22:35 | I haven’t seen the provexis.org site before ,seems to be a lot more information on it. .org sites are public information sites ,check it out | winner31 | |
30/4/2018 12:09 | Thanks. Not exactly a major shareholder here but holding long term now. If the Professor genuinely has discovered the major component of the Mediterranean diet which reduces mortality and morbidity to the extent which we think it does we ought to be in Nobel prize territory. Ok maybe not ha ha. | gunsofmarscapone | |
29/4/2018 12:25 | I am pretty sure DSM's lawyers will be keeping an eye on that too. | lafin | |
28/4/2018 19:05 | Guns it is the job of our directors to make sure all patents are kept up to date , as it is probably one of the few things they do at the you moment you would hope that they get that right. | winner31 | |
28/4/2018 12:08 | How does the (horribly complex) patent law apply to FruitFlow(tm) globally? ie if a new health claim is made and validated, for example systolic BP reduction do we have a new patent. Can anyone else feel a change in sentiment? I really think this is about to light up. | gunsofmarscapone | |
28/4/2018 09:23 | And there is still helps protect against air pollution,ED,high blood pressure etc.etc (and not just in China) | lafin | |
27/4/2018 20:53 | Objectives of Study: "To evaluate the health benefits of Fruitflow? (the water-soluble tomato extract) on the risk factors of cardiovascular disease in patients with the first diagnosis of hypercholesterolemia High Cholesterol. | twodegrees | |
27/4/2018 19:57 | Great find by Gixer on iii , could be the last piece of the puzzle imo | winner31 | |
24/4/2018 08:22 | Yes, very interesting indeed.Not being a research chemist I can't explain it properly but (and if I am right) is very good news. Also explains delays in products etc I am being deliberately vague as I am not a research chemist and nor is LibraG if he makes any comment. | lafin | |
24/4/2018 07:59 | Very interesting Chinese research find by Hammer on iii ,worth a read | winner31 | |
21/4/2018 19:00 | Wonder how this is selling, we should see some impact at the next trading update | winner31 | |
20/4/2018 14:02 | pump up the volume in £1,600 total 12:22:04 0.369 159,516 589 10:24:41 0.337 20,111 68 10:16:26 0.369 132,790 490 09:21:42 0.337 4,382 15 08:05:41 0.324 6,970 23 08:05:41 0.324 6,970 23 07:54:56 0.324 6,970 23 07:54:08 0.32 6,970 22 07:50:25 0.32 6,970 22 07:50:02 0.3 6,970 21 | buywell3 | |
19/4/2018 15:44 | “Besides, in 2018, BY-HEALTH will continue to develop in the field of sports nutrition, consolidate the market position of "GymMax, its sports nutrition brand, and build such symbolic facilities as transparent factory and nutrition exploratorium to further boost its brand power and service power. At present, the increasingly distinctive business development mode will form a solid foundation for the future development of the Company and is proceeding with a new growth cycle. Under the sound market conditions, BY-HEALTH will have exciting prospects for growth in 2018.” From 2017 results | winner31 | |
17/4/2018 22:57 | buywell, yes some crystallisation from the late 2016 spring buys but in deficit now. Last time I calculated it about 1k down on paper; slightly more now. What is left (not exactly a world class holding) will be a LTH. Absolutely brilliant product and I am exasperated at it’s failure so far to thrive. | gunsofmarscapone | |
13/4/2018 09:11 | Had an interesting email from provexis this morning targeted advertising ,but good to know they are still alive ! | winner31 | |
12/4/2018 15:47 | It wasn't me either Did any lucky worthy person get out at a 1p plus ? | buywell3 | |
04/4/2018 06:07 | Guns it was a hypothetical question ,its not me who owns £250ks worth! but I believe someone on these boards does ,they posted last year only the once ,my holding is much less than that . | winner31 | |
03/4/2018 23:38 | 50,000,000 shares? | gunsofmarscapone | |
03/4/2018 23:36 | 250k? thats quite astonishing! You are a Hnwi so can we assume that you are a creditor to Pxs rather than an individual building a holding in an equity portfolio? kr GoM | gunsofmarscapone | |
03/4/2018 19:15 | Not sure its apathy ,I wouldn't invest £250k in a tiny nutrient company without being shown some convincing prospects of getting a good return ,we live in hope | winner31 | |
31/3/2018 22:11 | The apathy is surprising really, given some of the single equity monomaniacs owning this nugget. | gunsofmarscapone | |
29/3/2018 18:33 | Where is the promised Chinese product? No explanation of the delay.Personally i have my doubts ...why would the Chinese want to release a product now when they can hold off and release one which entitles them to a share of the profit? Frankly we should have been told much more ling ago regarding specific reasons for non take up by large brand owners. I did ask at agm's but got zero support from shareholders.Shareho I know for a fact that lack of exclusivity was a major issue for one product that was pulled after much anticipation. Again i did ask about this too. Talking on bb's is all very well but where were the big holders at each agm?? | redprince | |
29/3/2018 11:44 | Looks like you may be looking at your chart from the inside out | lafin |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions